CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.

Antigens, CD20 Humans Lymphoma, B-Cell / therapy Prospective Studies Receptors, Chimeric Antigen / genetics Rituximab / therapeutic use Salvage Therapy T-Lymphocytes
CAR T-cell therapy CD20 Cytokine release syndrome (CRS) Non-Hodgkin lymphoma Rituximab

Journal

Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309

Informations de publication

Date de publication:
10 2022
Historique:
received: 05 01 2022
revised: 17 04 2022
accepted: 03 05 2022
pubmed: 13 6 2022
medline: 14 9 2022
entrez: 12 6 2022
Statut: ppublish

Résumé

The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safety of CD20 CAR T cells in rituximab-refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (B-NHL) patients, particularly those treated with rituximab for a short time. This prospective study aimed to assess the effectiveness and toxicity of CD20 CAR T cells in R/R B-NHL patients previously treated with rituximab. The authors conducted a prospective, single-center phase I study on the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350). A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and December 1, 2021. An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving complete remission and three (20%) achieving partial remission for the best response. The median follow-up time was 12.4 months. Progression-free survival and overall survival were not yet reached by the data cutoff day. No patient developed grade 4 cytokine release syndrome, and only one patient had immune effector cell-associated neurotoxicity syndrome. All enrolled B-NHL patients who were previously R/R to rituximab achieved different degrees of clinical response with tolerable toxicities. Notably, patients who had received rituximab within 3 months had a poorer prognosis.

Sections du résumé

BACKGROUND AIMS
The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safety of CD20 CAR T cells in rituximab-refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (B-NHL) patients, particularly those treated with rituximab for a short time. This prospective study aimed to assess the effectiveness and toxicity of CD20 CAR T cells in R/R B-NHL patients previously treated with rituximab.
METHODS
The authors conducted a prospective, single-center phase I study on the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350). A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and December 1, 2021.
RESULTS
An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving complete remission and three (20%) achieving partial remission for the best response. The median follow-up time was 12.4 months. Progression-free survival and overall survival were not yet reached by the data cutoff day. No patient developed grade 4 cytokine release syndrome, and only one patient had immune effector cell-associated neurotoxicity syndrome.
CONCLUSIONS
All enrolled B-NHL patients who were previously R/R to rituximab achieved different degrees of clinical response with tolerable toxicities. Notably, patients who had received rituximab within 3 months had a poorer prognosis.

Identifiants

DOI: 10.1016/j.jcyt.2022.05.001 PMID: 35691818
pubmed: 35691818
pii: S1465-3249(22)00640-5
doi: 10.1016/j.jcyt.2022.05.001
pii:
doi:

Substances chimiques

Antigens, CD20 0
Receptors, Chimeric Antigen 0
Rituximab 4F4X42SYQ6

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1026-1034

Informations de copyright

Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.

Auteurs

Qian Cheng (Q)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.

Jingwen Tan (J)

Shanghai UniCAR Therapy Biomedicine Technology Co, Ltd, Shanghai, China; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.

Rui Liu (R)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.

Liqing Kang (L)

Shanghai UniCAR Therapy Biomedicine Technology Co, Ltd, Shanghai, China.

Yi Zhang (Y)

Department of Gastrointestinal Surgery, Third Xiangya Hospital of Central South University, Changsha, China.

Erhua Wang (E)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.

Ying Li (Y)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.

Jian Zhang (J)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.

Han Xiao (H)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.

Nan Xu (N)

Shanghai UniCAR Therapy Biomedicine Technology Co, Ltd, Shanghai, China; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.

Minghao Li (M)

Shanghai UniCAR Therapy Biomedicine Technology Co, Ltd, Shanghai, China; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.

Lei Yu (L)

Shanghai UniCAR Therapy Biomedicine Technology Co, Ltd, Shanghai, China; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China. Electronic address: ylyh188@163.com.

Xin Li (X)

Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China. Electronic address: lixiner1975@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD20 › CD20-specific chimeric antigen...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › CD20-specific chimeric antigen...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › CD20-specific chimeric antigen...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › CD20-specific chimeric antigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs chimériques pour l'antigène › CD20-specific chimeric antigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux d'origine murine › Rituximab › CD20-specific chimeric antigen...
questionsmedicales.fr › Thérapeutique › Thérapie de rattrapage › CD20-specific chimeric antigen...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › CD20-specific chimeric antigen...